ARGOS THERAPEUTICS INC 4
4 · ARGOS THERAPEUTICS INC · Filed Jun 23, 2017
Insider Transaction Report
Form 4
Pharmstandard International S.A.
10% Owner
Transactions
- Purchase
Convertible Secured Promissory Note
2017-06-21(indirect: See footnote)Exercise: $0.50From: 2017-06-21Exp: 2022-06-21→ Common Stock (12,000,000 underlying)
Footnotes (2)
- [F1]This Convertible Secured Promissory Note (the "Note") was issued by the Issuer in principal amount of $6,000,000 for a purchase price of $6,000,000, and bears interest at a rate of 9.5% per annum. The Reporting Person may at any time and from time to time convert all outstanding principal and any accrued but unpaid interest under the Note into shares of the Issuer's common stock at a price per share equal to $0.50, subject to adjustment as provided in the Note.
- [F2]Pharmstandard International S.A. is a wholly owned subsidiary of Pharmstandard JSC. As the parent entity, Pharmstandard JSC has voting power over the shares of the Issuer held by Pharmstandard International S.A.